Health Care • Medical/Dental Instruments
$20.30 ▲ +0.10
(+0.50%)
MKT CAP: $1.16B • VOL: 704.6K
52W L $17 52W H $38
PRCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $308.1M | $224.5M | $136.2M |
| YoY Revenue Growth % | +37.2% | +64.8% | — |
| Gross Profit | $196.2M | $137.1M | — |
| Gross Margin % | 63.7% | 61.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$103.9M | -$96.6M | -$109.2M |
| Operating Margin % | -33.7% | -43.0% | -80.0% |
| Net Income (GAAP) | -$95.6K | -$91.4K | -$105.9K |
| EBITDA (Normalized) | -$96.4M | -$93.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.0M | -$99.2M | -$108.0M |
| Capital Expenditures (CapEx) | $9.4M | $4.4M | — |
| Free Cash Flow (FCF) | -$58.3M | -$103.6M | -$108.0M |
| FCF Margin % | -18.9% | -46.2% | -79.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $286.5M | $333.7M | — |
| Total Debt (Short + Long Term) | $51.6M | $51.5M | — |
| Total Stockholders' Equity | $365.9M | $402.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRCT.